All individual trials at M.D. Anderson Cancer Center
Trials reported
0 out of 0
Percent reported
—
US Govt could have imposed fines of at least
$0
Fines claimed by US Govt
$0
Showing 1 to 100 of 786 entries
Status | Sponsor | Trial ID | Title | Completion date | Days overdue |
---|---|---|---|---|---|
reported-late | M.D. Anderson Cancer Center | NCT01891968 | Phase II Study of Subcutaneous Bortezomib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome [pACT] | 2017-01-18 | 25 |
reported-late | M.D. Anderson Cancer Center | NCT02410551 | Pacritinib Prior to Transplant for Patients With Myeloproliferative Neoplasms (MPN) [pACT] | 2017-01-20 | 39 |
reported-late | M.D. Anderson Cancer Center | NCT01444742 | Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing After, or Are Refractory to, Hypomethylator Therapy [pACT] | 2017-01-29 | 43 |
reported-late | M.D. Anderson Cancer Center | NCT01272245 | A Phase II Study of Omacetaxine (OM) and Low Dose Cytarabine (LDAC) in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) [pACT] | 2017-01-31 | 47 |
reported-late | M.D. Anderson Cancer Center | NCT01746043 | A Randomized Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer [pACT] | 2017-01-31 | 51 |
reported-late | M.D. Anderson Cancer Center | NCT00422591 | Prospective Evaluation of Standard Chemotherapy Regimen of Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) [pACT] | 2017-01-31 | 26 |
reported | M.D. Anderson Cancer Center | NCT01924169 | A Study of Immune-adjuvant Effect of Lenalidomide in Patients With Chronic Lymphocytic Leukemia and Hypogammaglobulinemia and Impaired Response to Vaccinations - RV-CL-CLL-PI-002544 [pACT] | 2017-02-21 | |
reported-late | M.D. Anderson Cancer Center | NCT01174082 | Phase II Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant [pACT] | 2017-02-23 | 27 |
reported-late | M.D. Anderson Cancer Center | NCT00255346 | Therapy of Myeloid Metaplasia-Myelofibrosis, Atypical Chronic Myeloid or Myelomonocytic Leukemia, C-Kit Positive Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (AML-MDS), Hypereosinophilic Syndrome, Polycythemia Vera, and Mastocytosis With Dasatinib (BMS-354825) [pACT] | 2017-03-03 | 45 |
reported-late | M.D. Anderson Cancer Center | NCT01875237 | A Phase 1/2 Trial Evaluating Treatment of Emergent Graft Versus Host Disease (GvHD) With AP1903 After Planned Donor Infusions (DLIs) of T-cells Genetically Modified With the iCasp9 Suicide Gene in Patients With Hematologic Malignancies [pACT] | 2017-03-07 | 42 |
reported-late | M.D. Anderson Cancer Center | NCT00003645 | A Phase III Randomized Prospective Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence [pACT] | 2017-03-20 | 668 |
reported-late | M.D. Anderson Cancer Center | NCT00674479 | Phase II Study of INCB018424 in Patients With Advanced Hematologic Malignancies [pACT] | 2017-03-23 | 25 |
reported | M.D. Anderson Cancer Center | NCT01596127 | Safety and Efficacy of Intrathecal Rituximab in Patients With Lymphoid Malignancies Involving the Central Nervous System [pACT] | 2017-03-23 | |
reported-late | M.D. Anderson Cancer Center | NCT01096992 | A Phase I/II Clinical Trial of Fludarabine, Bendamustine, and Rituximab (FBR) in Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL) [pACT] | 2017-03-31 | 24 |
reported | M.D. Anderson Cancer Center | NCT00824993 | A Randomized, Controlled Study of Ibandronate for the Prevention of Bone Loss in Patients Who Have Received Allogeneic Bone Marrow Transplantation for Hematological Malignancies [pACT] | 2017-04-07 | |
reported-late | M.D. Anderson Cancer Center | NCT01377389 | A Phase II Study of Ipilimumab PLUS Androgen Depravation Therapy in Castrate Sensitive Prostate Carcinoma [pACT] | 2017-04-07 | 30 |
reported | M.D. Anderson Cancer Center | NCT01332630 | A Phase 2 Open-Label Study of TPI 287 in Patients With Breast Cancer Metastatic to the Brain [pACT] | 2017-04-14 | |
reported-late | M.D. Anderson Cancer Center | NCT01169636 | Phase I Study of Panobinostat Plus ICE Chemotherapy Followed by a Randomized Phase-II Study of ICE Compared With Panobinostat Plus ICE for Patients With Relapsed and Refractory Classical Hodgkin Lymphoma [pACT] | 2017-05-17 | 763 |
reported-late | M.D. Anderson Cancer Center | NCT02623959 | A Double Blind Randomized Controlled Trial of Indwelling Pleural Catheters Versus Indwelling Pleural Catheters Plus Doxycycline Pleurodesis for Treatment of Malignant Pleural Effusions [pACT] | 2017-05-23 | 328 |
reported-late | M.D. Anderson Cancer Center | NCT02337686 | Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma [pACT] | 2017-05-24 | 1574 |
reported | M.D. Anderson Cancer Center | NCT02302846 | Phase II Study Of Ixazomib As Maintenance Therapy For Patients With Acute Myeloid Leukemia (AML) And High Risk Myelodysplastic Syndrome (MDS) In Remission [pACT] | 2017-05-30 | |
reported | M.D. Anderson Cancer Center | NCT02469415 | Phase II Study of Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes [pACT] | 2017-06-03 | |
reported | M.D. Anderson Cancer Center | NCT01994590 | A Phase II Study of Dovitinib (TKI258) Combined With Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer Evaluating Markers of FGF and AR Signaling in Bone Marrow and Plasma [pACT] | 2017-06-05 | |
reported | M.D. Anderson Cancer Center | NCT00916578 | A Phase II Study of Preoperative Capecitabine and Concomitant Radiation in Women With Advanced Inflammatory or Non-Inflammatory Breast Cancer [pACT] | 2017-06-06 | |
reported | M.D. Anderson Cancer Center | NCT02420873 | An Open-label Phase II Study of Lorvotuzumab Mertansine (IMGN901) in CD56 Expressing Hematological Malignancies [pACT] | 2017-06-06 | |
reported | M.D. Anderson Cancer Center | NCT01692197 | A Phase 2 Study of E7070, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndromes [pACT] | 2017-06-07 | |
reported-late | M.D. Anderson Cancer Center | NCT00831792 | An Observational Study of Continuous TKI258, in Castration-Resistant Prostate Cancer Patients Evaluating Markers of FGF Signaling in Bone Marrow Plasma [pACT] | 2017-06-12 | 289 |
reported | M.D. Anderson Cancer Center | NCT00495040 | Phase II Escalated/Accelerated Proton Radiotherapy for Inoperable Stage I (T1-T2, N0, M0) and Selected Stage II (T3N0M0) Non-Small Cell Lung Cancer (NSCLC) [pACT] | 2017-06-14 | |
reported | M.D. Anderson Cancer Center | NCT00495170 | Phase II Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) [pACT] | 2017-06-14 | |
reported | M.D. Anderson Cancer Center | NCT01388777 | A Pilot Study to Determine the Efficacy of Cryoablation for the Treatment of Invasive Breast Carcinoma Following Neoadjuvant Therapy [pACT] | 2017-06-14 | |
reported | M.D. Anderson Cancer Center | NCT01432171 | Randomized, Double-Blind, Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients With High-Grade Gliomas [pACT] | 2017-06-20 | |
reported | M.D. Anderson Cancer Center | NCT02419469 | Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma [pACT] | 2017-06-22 | |
reported | M.D. Anderson Cancer Center | NCT01289457 | Phase I/II Randomized Study of Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome [pACT] | 2017-06-28 | |
reported-late | M.D. Anderson Cancer Center | NCT00414076 | A Randomized Phase II Study of Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma [pACT] | 2017-07-13 | 27 |
reported-late | M.D. Anderson Cancer Center | NCT00271505 | A Phase II Evaluation of Avastin in Combination With Docetaxel and Carboplatin as Chemotherapy in Patients With Metastatic Non-Small Cell Lung Cancer [pACT] | 2017-07-27 | 621 |
reported-late | M.D. Anderson Cancer Center | NCT01946165 | A Pre-Operative Study to Assess the Effects of Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide for Six Months for Prostate Cancer Patients at High-Risk for Recurrence [pACT] | 2017-07-28 | 165 |
reported-late | M.D. Anderson Cancer Center | NCT00290498 | A Phase II Randomized Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger [pACT] | 2017-08-11 | 486 |
reported | M.D. Anderson Cancer Center | NCT02169505 | Safety and Efficacy of Brentuximab Vedotin Maintenance After Allogeneic and Haploidentical Stem Cell Transplantation in High Risk CD30+ Lymphoma (Hodgkin Lymphoma and ALCL) [pACT] | 2017-08-14 | |
reported-late | M.D. Anderson Cancer Center | NCT01263782 | BATTLE-FL: A Biomarker-Integrated Study in Patients With Advanced Non-Small Cell Lung Cancer Treated in the Front-Line (FL) Setting [pACT] | 2017-08-15 | 26 |
reported-late | M.D. Anderson Cancer Center | NCT02271906 | The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting [pACT] | 2017-08-16 | 105 |
reported | M.D. Anderson Cancer Center | NCT02596711 | Project Impact 2: A Culturally Tailored Smoking Cessation Intervention for Latino Smokers [pACT] | 2017-08-22 | |
reported-late | M.D. Anderson Cancer Center | NCT00577993 | Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) for Stage IV Indolent Lymphoma [pACT] | 2017-08-24 | 594 |
reported-late | M.D. Anderson Cancer Center | NCT00254410 | Phase 2 Study of the Activity and Safety of Fludarabine, Cyclophosphamide, and Mitoxantrone Plus Rituximab (FCM-R) With Pegfilgrastim (Neulasta) as Frontline Therapy for Patients < 70 Years With Chronic Lymphocytic Leukemia [pACT] | 2017-09-14 | 60 |
reported | M.D. Anderson Cancer Center | NCT01237951 | High-dose Gemcitabine, Busulfan and Melphalan With Autologous Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma [pACT] | 2017-09-20 | |
reported-late | M.D. Anderson Cancer Center | NCT00475020 | Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome Using Reduced Intensity Busulfan and Fludarabine Conditioning [pACT] | 2017-10-04 | 34 |
reported-late | M.D. Anderson Cancer Center | NCT01010217 | Three-arm Clinical Trial for Patients With Hematologic Malignancies and Mismatched Donors - Haploidentical, 1 Antigen Mismatch Related or Unrelated, and Matched Unrelated Donor (MUD)- Using a T-cell Replete Allograft and High-dose Post-transplant Cyclophosphamide [pACT] | 2017-10-05 | 222 |
reported-late | M.D. Anderson Cancer Center | NCT01438476 | Randomized Controlled Trial of Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient Controlled Analgesia (3:1) in Patients Undergoing Liver and/or Pancreatic Resection [pACT] | 2017-10-18 | 462 |
reported-late | M.D. Anderson Cancer Center | NCT01983969 | Azacitidine/Vorinostat/GemBuMel With Autologous Stem-Cell Transplant (SCT) in Patients With Refractory Lymphomas [pACT] | 2017-11-22 | 145 |
reported-late | M.D. Anderson Cancer Center | NCT00500890 | A Pilot Study Evaluating the Feasibility of an Intercontinental Phase III Chemotherapy Study for Patients With Choroid Plexus Tumors [pACT] | 2017-12-14 | 424 |
reported-late | M.D. Anderson Cancer Center | NCT02042950 | A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma [pACT] | 2017-12-20 | 110 |
reported | M.D. Anderson Cancer Center | NCT02272686 | Targeting Bruton's Tyrosine Kinase (BTK) With Ibrutinib After Autologous Stem Cell Transplantation in "Double-Hit" B-Cell Lymphoma [pACT] | 2017-12-22 | |
reported-late | M.D. Anderson Cancer Center | NCT01794702 | Phase I/II Study of Decitabine (DAC) Followed by Clofarabine, Idarubicin, and Cytarabine (CIA) in Acute Leukemia [pACT] | 2018-01-11 | 28 |
reported | M.D. Anderson Cancer Center | NCT01002755 | Combination of Lenalidomide and Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) [pACT] | 2018-01-31 | |
reported-late | M.D. Anderson Cancer Center | NCT01277744 | A Phase II Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor and Other Non-Carcinomas [pACT] | 2018-02-16 | 208 |
reported-late | M.D. Anderson Cancer Center | NCT00411632 | A Phase II Study of Erlotinib (Tarceva) in Combination With Bexarotene (Targretin) in Chemorefractory Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) [pACT] | 2018-02-23 | 192 |
reported-late | M.D. Anderson Cancer Center | NCT01208103 | Phase II Study of Bevacizumab Combined With Capecitabine and Oxaliplatin (CAPOX) in Patients With Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater [pACT] | 2018-03-07 | 243 |
reported | M.D. Anderson Cancer Center | NCT02274493 | Pilot Study of Robotic-Assisted Harvest of the Latissimus Dorsi Muscles [pACT] | 2018-03-07 | |
reported-late | M.D. Anderson Cancer Center | NCT00352794 | Evaluation of Lenalidomide (CC-5013) and Prednisone as a Therapy for Patients With Myelofibrosis (MF) [pACT] | 2018-03-08 | 46 |
reported | M.D. Anderson Cancer Center | NCT01253460 | A Phase II Clinical Trial of Sapacitabine, Cyclophosphamide, and Rituximab (SCR) for Relapsed Patients With Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) and Deletion 11q22-23 by FISH [pACT] | 2018-03-28 | |
reported-late | M.D. Anderson Cancer Center | NCT01000051 | Eltrombopag for Post Transplant Thrombocytopenia [pACT] | 2018-04-04 | 75 |
reported-late | M.D. Anderson Cancer Center | NCT02421354 | Phase 2 Study of Nivolumab in Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis [pACT] | 2018-04-13 | 10 |
reported-late | M.D. Anderson Cancer Center | NCT01134575 | Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) With CMC-544 (Inotuzumab Ozogamycin), With or Without Later Addition of Rituximab [pACT] | 2018-04-18 | 12 |
reported-late | M.D. Anderson Cancer Center | NCT01706705 | 3D Image-guided Intracavitary Brachytherapy Treatment Planning for Cervical Cancer Using a Novel Shielded Applicator [pACT] | 2018-04-22 | 134 |
reported | M.D. Anderson Cancer Center | NCT01629511 | Clofarabine, Gemcitabine, and Busulfan Followed by Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) [pACT] | 2018-04-25 | |
reported-late | M.D. Anderson Cancer Center | NCT02282345 | A Pilot Study of Talazoparib as a Neoadjuvant Study in Patients With a Diagnosis of Invasive Breast Cancer and a Deleterious BRCA Mutation [pACT] | 2018-04-26 | 966 |
reported-late | M.D. Anderson Cancer Center | NCT02530515 | Trial of Immune Reconstitution With Activated T-Cells in Patients With Chronic Lymphocytic Leukemia (CLL) [pACT] | 2018-04-30 | 92 |
reported-late | M.D. Anderson Cancer Center | NCT00967369 | A Randomized Phase II Study of Bortezomib Plus ICE (BICE) Versus Standard ICE for Patients With Relapsed/Refractory Classical Hodgkin Lymphoma [pACT] | 2018-05-02 | 6 |
reported | M.D. Anderson Cancer Center | NCT00946270 | A Phase II, Prospective, Open Label Study (PO-MMM-PI-0011) to Determine the Safety and Efficacy of Pomalidomide (CC-4047) in Subjects With Primary, Post Polycythemia Vera, or Post Essential Thrombocythemia Myelofibrosis (PMF; Post-PV MF, or Post-ET MF) [pACT] | 2018-05-22 | |
reported-late | M.D. Anderson Cancer Center | NCT00563784 | A Phase II Study of TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) [pACT] | 2018-05-30 | 96 |
reported-late | M.D. Anderson Cancer Center | NCT01900730 | Randomized Phase II Double Blind Study of Valproic Acid (VPA) vs Placebo to Shorten Time of Indwelling Pleural Catheter [pACT] | 2018-06-01 | 230 |
reported | M.D. Anderson Cancer Center | NCT02267278 | Evaluation of Ruxolitinib and Pracinostat Combination as a Therapy for Patients With Myelofibrosis [pACT] | 2018-06-01 | |
reported-late | M.D. Anderson Cancer Center | NCT00402779 | Erlotinib Prevention of Oral Cancer (EPOC) [pACT] | 2018-06-04 | 258 |
reported-late | M.D. Anderson Cancer Center | NCT00439556 | Bortezomib (Velcade®) and Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoid Malignancies [pACT] | 2018-06-07 | 49 |
reported-late | M.D. Anderson Cancer Center | NCT02389764 | A Phase II Study of BIBF1120 (Nintedanib) for Patients With Metastatic HER2-Negative Inflammatory Breast Cancer (IBC) [pACT] | 2018-06-08 | 18 |
reported-late | M.D. Anderson Cancer Center | NCT01202409 | Phase II Study of Panitumumab in KRAS Wild-type Locally Advanced or Metastatic Adenocarcinoma of the Small Bowel or Ampulla of Vater [pACT] | 2018-07-03 | 20 |
reported-late | M.D. Anderson Cancer Center | NCT02727777 | Phase II Study of TAK228 in Relapsed Lymphoma | 2018-07-10 | 93 |
reported-late | M.D. Anderson Cancer Center | NCT00129740 | Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Oral Nilotinib [pACT] | 2018-07-11 | 39 |
reported-late | M.D. Anderson Cancer Center | NCT02399917 | An Open-Label Phase II Study of Lirilumab (BMS-986015) in Combination With 5-Azacytidine (Vidaza) for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia [pACT] | 2018-07-12 | 34 |
reported | M.D. Anderson Cancer Center | NCT00966693 | Phase I/II Study of Lenalidomide (Revlimid), Thalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma [pACT] | 2018-07-20 | |
reported-late | M.D. Anderson Cancer Center | NCT00866749 | Augmented Berlin-Frankfurt-Munster Therapy for Adolescents/Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma [pACT] | 2018-07-26 | 5 |
reported-late | M.D. Anderson Cancer Center | NCT01520519 | A Phase 2 Study of the Combination of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients [pACT] | 2018-08-09 | 10 |
reported-late | M.D. Anderson Cancer Center | NCT01752426 | A Pilot Study to Determine the Effects of the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) [pACT] | 2018-08-09 | 18 |
reported-late | M.D. Anderson Cancer Center | NCT00957853 | An Exploratory Study to Assess the Modulation of Biomarkers in Patients With Squamous Cell Carcinomas of the Head and Neck Randomized to Receive Preoperative Treatment With Cetuximab and/or IMC-A12, an Anti-insulin-like Growth Factor-1 Receptor Monoclonal Antibody [pACT] | 2018-08-15 | 153 |
reported-late | M.D. Anderson Cancer Center | NCT00887068 | Randomized Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) [pACT] | 2018-08-20 | 121 |
reported | M.D. Anderson Cancer Center | NCT03138967 | A Phase IV Investigation of Sugammadex in Outpatient Urological Procedures | 2018-09-01 | |
reported | M.D. Anderson Cancer Center | NCT01375140 | Evaluation of Ruxolitinib and Lenalidomide Combination as a Therapy for Patients With Myelofibrosis [pACT] | 2018-09-05 | |
reported-late | M.D. Anderson Cancer Center | NCT00654732 | A Randomized Phase II Study of Rituximab With ABVD Versus Standard ABVD for Patients With Advanced-Stage Classical Hodgkin Lymphoma With Poor Risk Features (IPS Score > 2) [pACT] | 2018-09-05 | 152 |
reported-late | M.D. Anderson Cancer Center | NCT01693523 | A Randomized, Placebo Controlled-Double Blind Study of Minocycline for Reducing the Symptom Burden for Pancreatic Cancer Patients [pACT] | 2018-09-19 | 132 |
reported-late | M.D. Anderson Cancer Center | NCT02597478 | A Preliminary Study of Prophylactic Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea [pACT] | 2018-09-27 | 398 |
reported | M.D. Anderson Cancer Center | NCT03210376 | The Effect of Deep Neuromuscular Blockade With Sugammadex Reversal on Shoulder Pain of Elderly Patients Undergoing Robotic Surgery: A Single-Center Double-Blinded Randomized Controlled Trial | 2018-09-30 | |
reported | M.D. Anderson Cancer Center | NCT00899431 | Nonmyeloablative Stem Cell Transplantation With or Without Lenalidomide for Chronic Lymphocytic Leukemia (RV-CLL-PI-0294) [pACT] | 2018-10-07 | |
reported | M.D. Anderson Cancer Center | NCT01952054 | Phase II Study of Denosumab to Define the Role of Bone Related Biomarkers in Breast Cancer Bone Metastasis [pACT] | 2018-10-10 | |
reported-late | M.D. Anderson Cancer Center | NCT01664897 | A Pilot Phase II Study of Erlotinib for the Treatment of Patients With Refractory/Relapsed AML [pACT] | 2018-10-25 | 12 |
reported | M.D. Anderson Cancer Center | NCT01266603 | A Phase II Trial of High Dose Interleukin-2 (HDIL-2) With Recombinant MAGE-A3 Protein Combined With Adjuvant System AS15 (recMAGE-A3 + AS15) in Patients With Unresectable or Metastatic Melanoma [pACT] | 2018-11-01 | |
reported-late | M.D. Anderson Cancer Center | NCT02196857 | Phase II Study of Sorafenib Plus 5-Azacitidine for the Initial Therapy of Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome With FLT3-ITD Mutation [pACT] | 2018-11-27 | 20 |
reported | M.D. Anderson Cancer Center | NCT00338728 | Phase II Study of Letrozole (Femara) Plus Imatinib Mesylate (Gleevec) for Postmenopausal Patients With ER and/or PR Positive Metastatic Breast Cancer [pACT] | 2018-11-27 | |
reported | M.D. Anderson Cancer Center | NCT01200329 | High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic Cell Support for Patients With Relapsed/Refractory Hodgkin's Disease [pACT] | 2018-12-06 | |
reported | M.D. Anderson Cancer Center | NCT02060370 | A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC) [pACT] | 2019-01-02 | |
reported | M.D. Anderson Cancer Center | NCT02010645 | Phase II Study of Eltrombopag in Combination With Decitabine in Subjects With Advanced Myelodysplastic Syndrome [pACT] | 2019-01-02 | |
reported | M.D. Anderson Cancer Center | NCT02285855 | Tumor Mutation Status Will Predict Metabolic Response to Metformin in Non Small Cell Lung Cancer (NSCLC) [pACT] | 2019-01-05 |